SKU:  PME101592     Target:  PD-L1

Price: 10μg $96.00 ; 50μg $370.00 ; 100 μg $555.00

SKU:  PME101591     Target:  PD-L1

Price: 10μg $96.00 ; 50μg $370.00 ; 100 μg $555.00

SKU:  PME101706     Target:  PD-L1

Price:10μg $96.00 ; 50μg $370.00 ; 100 μg $555.00


Posts found

Dual-Payload ADCs: The Next Big Thing in the ADC Arena

Efforts to improve traditional ADCs have primarily focused on the three key components: the antibody, [...]

Popular Targets in the Bispecific ADC Pipeline

At the 2025 AACR Annual Meeting, Chinese ADC drugs have emerged in various forms such [...]

China’s Growing Impact on ADC Development at AACR 2025

The 2025 American Association for Cancer Research (AACR) Annual Meeting is set to take place [...]

CD73: A Potential Target in Cancer Immunotherapy

On September 25, 2024, I-Mab announced a strategic collaboration with Sanofi to develop, produce, and [...]

HER3/ERBB3: Dominating Cancer Therapy with ADCs and Beyond

On September 17, a collaboration between Daiichi Sankyo and Merck announced that patritumab deruxtecan, a [...]

Research Progress on BCMA-Targeted Therapies in Multiple Myeloma

On August 27, 2024, Legend Biotech’s BCMA CAR-T product, Carvykti® (generic name: ciltacabtagene autoleucel injection), [...]

Nectin-4: A Promising Target in Antibody-Drug Conjugate (ADC) Therapy

During the 2024 ASCO conference, Professor Zhang Jian of Fudan University’s Cancer Hospital unveiled the [...]

Immune Checkpoint B7-H3: Exploring the Current Landscape of Targeted Therapies

In December 2023, GlaxoSmithKline (“GSK”) invested $1.71 billion to obtain the global exclusive rights for [...]

Tumor Immune Target – Claudin18.2

Since Ganymed unveiled the efficacy data of Zolbetuximab (IMAB362), the anti-Claudin18.2 monoclonal antibody, for the [...]

GPC3, a Popular Target in Liver Cancer Treatment

On December 7, 2023, AbelZeta announced a collaboration with AstraZeneca to jointly develop C-CAR031, a [...]


Pages found